Javascript must be enabled to continue!
Data from Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
View through CrossRef
<div>AbstractPurpose:<p>Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strategies have been established. This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome analysis and assess the preclinical efficacy of novel drug candidates.</p>Experimental Design:<p>Transcriptome analysis was performed using fresh-frozen samples of six uterine leiomyosarcomas and three myomas. The Ingenuity Pathway Analysis (IPA) was used to identify potential therapeutic target genes for uterine leiomyosarcoma. Afterward, our results were validated using three independent datasets, including 40 uterine leiomyosarcomas. Then, the inhibitory effects of several selective inhibitors for the candidate genes were examined using SK-UT-1, SK-LMS-1, and SKN cell lines.</p>Results:<p>We identified 512 considerably dysregulated genes in uterine leiomyosarcoma compared with myoma. The IPA revealed that the function of several genes, including CHEK1 and PLK1, were predicted to be activated in uterine leiomyosarcoma. Through an <i>in vitro</i> drug screening, PLK1 or CHEK1 inhibitors (BI-2536 or prexasertib) were found to exert a superior anticancer effect against cell lines at low nanomolar concentrations and induce cell-cycle arrest. In SK-UT-1 tumor-bearing mice, BI-2536 monotherapy remarkably suppressed tumorigenicity. Moreover, the prexasertib and cisplatin combination therapy inhibited tumor proliferation and prolonged the time to tumor progression.</p>Conclusions:<p>We identified upregulated expressions of <i>PLK1</i> and <i>CHEK1</i>; their kinase activity was activated in uterine leiomyosarcoma. BI-2536 and prexasertib demonstrated a significant anticancer effect. Therefore, cell-cycle–related kinases may present a promising therapeutic strategy for the treatment of uterine leiomyosarcoma.</p></div>
American Association for Cancer Research (AACR)
Title: Data from Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
Description:
<div>AbstractPurpose:<p>Uterine leiomyosarcoma is among the most aggressive gynecological malignancies.
No effective treatment strategies have been established.
This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome analysis and assess the preclinical efficacy of novel drug candidates.
</p>Experimental Design:<p>Transcriptome analysis was performed using fresh-frozen samples of six uterine leiomyosarcomas and three myomas.
The Ingenuity Pathway Analysis (IPA) was used to identify potential therapeutic target genes for uterine leiomyosarcoma.
Afterward, our results were validated using three independent datasets, including 40 uterine leiomyosarcomas.
Then, the inhibitory effects of several selective inhibitors for the candidate genes were examined using SK-UT-1, SK-LMS-1, and SKN cell lines.
</p>Results:<p>We identified 512 considerably dysregulated genes in uterine leiomyosarcoma compared with myoma.
The IPA revealed that the function of several genes, including CHEK1 and PLK1, were predicted to be activated in uterine leiomyosarcoma.
Through an <i>in vitro</i> drug screening, PLK1 or CHEK1 inhibitors (BI-2536 or prexasertib) were found to exert a superior anticancer effect against cell lines at low nanomolar concentrations and induce cell-cycle arrest.
In SK-UT-1 tumor-bearing mice, BI-2536 monotherapy remarkably suppressed tumorigenicity.
Moreover, the prexasertib and cisplatin combination therapy inhibited tumor proliferation and prolonged the time to tumor progression.
</p>Conclusions:<p>We identified upregulated expressions of <i>PLK1</i> and <i>CHEK1</i>; their kinase activity was activated in uterine leiomyosarcoma.
BI-2536 and prexasertib demonstrated a significant anticancer effect.
Therefore, cell-cycle–related kinases may present a promising therapeutic strategy for the treatment of uterine leiomyosarcoma.
</p></div>.
Related Results
Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significance
Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significance
Abstract
Purpose
Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strateg...
Identification of PLK1 as a proviral factor for the hepatitis B virus replication : A possible target for antiviral and anticancerous drug development
Identification of PLK1 as a proviral factor for the hepatitis B virus replication : A possible target for antiviral and anticancerous drug development
Développement et utilisation d'ARN interférents dirigés contre PLK1 dans le cadre d'une infection chronique par le virus de l'hépatite B
Dans les régions de fortes ...
Abstract 5172: Mechanistic insights into PLK1 target inhibition in ovarian cancer: Functional suppression and PROTAC-based therapeutic agents
Abstract 5172: Mechanistic insights into PLK1 target inhibition in ovarian cancer: Functional suppression and PROTAC-based therapeutic agents
Abstract
OBJECTIVE:
This study aimed to identify the oncogenic role of PLK1(Polo-like kinase 1) in ovarian cancer and eva...
Abstract 3459: Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma
Abstract 3459: Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma
Abstract
Mantle cell lymphoma (MCL) is an incurable, aggressive B cell malignancy. Ibrutinib, an oral irreversible Bruton's tyrosine (BTK) inhibitor, was FDA-approve...
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract
OBJECTIVE:
Colorectal cancer is a cancer with high prevalence and mortality rates worldwide, treated with surger...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
UBAP2L-dependent coupling of PLK1 localization and stability during mitosis
UBAP2L-dependent coupling of PLK1 localization and stability during mitosis
Abstract
PLK1 is an important regulator of mitosis whose protein levels and activity fluctuate during the cell cycle. PLK1 dynamically localizes to various mitotic ...
Abstract 1133: Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state
Abstract 1133: Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state
Abstract
One outcome of activation of the PI3K pathway is increased aerobic glycolysis, but the upstream signaling events that regulate the PI3K pathway, thus the Wa...

